ImmunoPrecise Antibodies Ltd (IPA)

[MonstaGains]

I know im holding at least some for tomorrow

[Up/DownTrader]

Been gone all day, behind DMV & kids! Should I get this TOMORROW, Lord 'M-G'!!!??? I'm scrambling on this Board behind all your DD, etc.!!!

[SmokeSignals]

ok genius

[jr525]

Lol no shot

[SmokeSignals]

could run to $70 imo

[europtiger]

Re entry at 12,30

[stockdawg44]

12's might hold, maybe lol

[Nebuchadnezzar]

nice call and alert on IPA MonstaGains

[stockdawg44]

13.00 Support 4 now IPA

[masterofdisaster]

Lolol right

[Foxbat426]

Who’s going to be caught holding the bag!! That’s the question.

[MonstaGains]

Break new HOD and its on!

[europtiger]

Going again

[johnet]

Ask at $20!

[MonstaGains]

HUGE!!!!!!!!

[europtiger]

Boom

[MonstaGains]

YES!!!!! NEW HOD!!!!!!!!!

[europtiger]

15 easy imo… off to Golf.

[MonstaGains]

This can be huge!!!!!!!!

[MonstaGains]

SQUEEZE THE SHORTS!

[europtiger]

Float 19 milli has been tradet allready

[MonstaGains]

She moves like butter

[europtiger]

Looking good so far

[MonstaGains]

This could run like NURO! HUGE NEWS today!

[europtiger]

Just got 9,20‘s

[MonstaGains]

Wow! After today imma drink a IPA hahaha

[MonstaGains]

HUGE NEWS!!!!!!!!!!!!!

[Mr Fox]

TRANSVAC2 funds a Collaboration between
European and US/Canadian SMEs
on a unique, single-shot SARS-CoV-2 vaccine
LiteVax BV (Oss, the Netherlands), ImmunoPrecise Antibodies (Oss, the Netherlands and Victoria,
Canada) and IRTA (Barcelona, Spain) decided to combine their respective expertise in the field of
immunoadjuvants, antigen design and vaccination evaluation, to develop an effective and safe SARSCoV-2 vaccine for the globe. Feasibility of single-shot approach will be evaluated in large, nonrodent
species by measuring neutralizing antibody responses and immunological memory. Based on results with
similar experimental vaccines, expectations are high. The project is sponsored by TRANSVAC2, a network
of leading European groups working in the field of vaccine R&D and funded by the European Commission
(EC grant agreement N° 730964).
ImmunoPrecise Antibodies exploits it’s PolyTopeTM monoclonal antibody platform for the treatment of
patients against SARS-CoV-2 infection. The platform is of particular interest to identify and optimize
neutralizing epitopes and to design promising antigen candidates. A selection of unique, rationaldesigned subunits will be investigated. LiteVax exploits a novel class of synthetic carbohydrate
derivatives as vaccine adjuvant and preclinical data demonstrate that high responses and strong
immunological memory are obtained already after a first vaccination. As service provider in this
collaboration, IRTA (Barcelona) has all relevant expertise, know-how and facilities to conduct vaccination
studies in large animal species including SARS-CoV-2 vaccines.
With the many COVID19-vaccine initiatives in advanced stage of development, opportunities for new
candidates are controlled activation and modulation of the immune system; high and persistent
immunity, strong memory and no immune-enhanced disease are key. Provided that results are
promising, the project will be a first stepping stone towards clinical development and commercialization
of the concept. Funding by TRANSVAC2/EU acts as a catalyst to crossing boundaries and building an
inspiring collaboration between parties with complementary technologies. By this transatlantic
collaboration we hope to contribute to the idea that global problems should be solved together.

[Renee]

IPATF changed to IPA. Moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Mr Fox]

Last day trading on the Otc, tomorrow Nasdaq. New all time high coming?

[Renee]

IPATF: effective Nov. 23,2020 a one for 5 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[Simbeez]

Look for a nice pop up tomorrow morning, the CEO (Jennifer Bath) will have a live interview on BNN Bloomberg in Canada. It's at 11:30 am Eastern, 8:30 Pacific. Interview happening during trading session.

[Simbeez]

Dr. Jennifer Bath, CEO of @ImmunoPrecise will be Live Oct. 4th 7:15amET on
@foxandfriends

@FoxNews

[spec machine]

That's a beautiful chart

spec

[Py11]

[ronpopeil]

Ceo to be on Bloomberg Monday after the close


https://www.bloomberg.com/series/bloomberg-technology

[spec machine]

Should see another green day today

GLTA

spec

[ronpopeil]

https://finance.yahoo.com/news/gatineau-key-player-quebecs-economy-151700991.html

[ronpopeil]

https://sec.report/Document/0001193125-20-247166/d20922d40fr12b.htm

[Py11]

Here we go!

[Py11]

IPA is looking great. CEO is meeting with investors this week and presenting at LD Micro on Friday. I believe we’ll be seeing a lot of news going forward as they will be uplisting to Nasdaq in near future. Warrants are providing a little selling pressure - if it wasn’t for the warrants we’d be a lot higher. Really excited for the next month and post Nasdaq listing.

[ronpopeil]

[ronpopeil]

https://cloudflare-ipfs.com/ipfs/QmWMxrJwAVisJzUmr8chgoHosk58rK8VzqngWfSryXkRye

[ronpopeil]

Yes, the presentation was very positive and it’s great to see them get the grant. Obtaining more funding through darpa will be great. If they can land a big pharmaceutical deal with a sizeable upfront payment, it could be a game changer. It sounds like they are close. Hopefully we see something significant soon

[Py11]

It was a great presentation. After listening to Jennifer I’m confident that they’ll get some federal funding from DARPA/BARDA. In talks with 6-7 large pharmas for out licensing deals. Sounds like they’ll be taking their Polytope therapy as far as possible before a likely partnership with big pharma. That will be the biggest deal.

[ronpopeil]

https://vimeo.com/441407203

[ronpopeil]

[ronpopeil]

I would think so

[Py11]

A big pharma partnership has to be coming soon. IPA has such a massive Covid mAb library and with already having relationships with many pharmas for their CRO business, I’d expect at least one of them to get involved.

[ronpopeil]

https://cordis.europa.eu/article/id/421550-supporting-faster-coronavirus-vaccine-production